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Abstract  Since  there  are  salvage  solutions,  it  is  important  to  detect  local  recurrence  of
prostate cancer  as  early  as  possible.  The  ﬁrst  sign  is  ‘‘biochemical  failure’’  in  that  the
prostate speciﬁc  antigen  (PSA)  concentration  rises  again.  The  deﬁnition  of  biochemical  failure
varies depending  on  the  initial  treatment:  PSA  greater  than  0.2  ng/mL  after  prostatectomy,
nadir +  2  ng/mL  after  radiotherapy.  There  is  no  standardised  deﬁnition  of  biochemical  failure
after cryotherapy,  focused  ultrasound,  or  brachytherapy.  Magnetic  resonance  imaging  (MRI)
(particularly  dynamic  MRI)  can  detect  local  recurrence  with  good  sensitivity.  The  role  of
spectroscopy  is  still  under  discussion.  For  the  moment,  ultrasound  techniques  are  less  effective
than MRI.
©  2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Over  the  past  20  years,  the  therapeutic  arsenal  against  localised  prostate  cancer  has
grown  considerably.  Brachytherapy  [1],  cryotherapy  [2],  focused  ultrasound  ablation  [2,3]
and  photodynamic  therapy  [4]  have  been  added  to  the  classic  treatment  methods  of
prostatectomy  and  radiotherapy.  These  therapies  are  not  only  new  weapons  in  the  initial
management  of  prostate  cancer,  but  also  in  salvage  treatment  in  cases  of  local  recurrence.
Now,  regardless  of  the  initial  treatment,  there  are  several  salvage  solutions  if  there  is
a  local  setback  [5].
It  is  therefore  essential  to  detect  local  recurrence  and  locate  it  precisely  so  that  salvage
treatment  may  be  undertaken  under  the  best  possible  conditions.  Imaging  local  recur-
rence  is  currently  a growing  ﬁeld,  not  only  because  of  the  clinical  need  for  it,  but  also
because  initial  assessments  have  indicated  that  detection  and  localisation  of  tumour  foci
are  paradoxically  easier  and  more  precise  for  local  recurrence  than  for  untreated  cancer.
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metastases  do  exist  when  biochemical  failure  is  found,  they
are  generally  microscopic  and  are  highly  likely  to  be  missed80  
The  purpose  of  this  paper  is  to  review  the  indications
or  imaging,  the  techniques  to  be  used  and  the  possible
esults  for  patients  with  suspected  local  recurrence  after
nitial  treatment  of  their  prostate  cancer.
here it all (re)starts: biochemical failure
maging  is  not  indicated  for  monitoring  treated  patients.
he  ﬁrst  warning  sign  is  an  increase  again  in  PSA
oncentration  above  a  given  threshold.  Precise  deﬁni-
ion  of  this  biochemical  failure  depends  on  the  initial
reatment  (Table  1).
fter radical prostatectomy
SA  should  theoretically  be  undetectable.  Ofﬁcially,  a
atient  will  be  having  a  biochemical  failure  when  the  PSA
oncentration  exceeds  0.2  ng/mL  [6].
fter radiotherapy
ere,  on  the  contrary,  the  PSA  concentration  falls  very
lowly  with  a  low  point  (nadir)  reached  after  2  to  4  years.
or  a  long  time,  biochemical  failure  was  deﬁned  according  to
he  ASTRO  guidelines  (three  successive  rises  after  the  nadir,
he  date  of  recurrence  being  backdated  as  the  point  halfway
etween  the  ﬁrst  and  second  rise).  This  criterion  correlated
oorly  with  survival  and  was  replaced  in  2005  by  the  Phoenix
riterion  (a  rise  in  PSA  concentration  of  2  ng/mL  above  the
adir)  [7].
fter focused ultrasound ablation
here  is  no  ofﬁcial  deﬁnition  of  recurrence  in  this  case.  A
trip  of  anterior  prostate  tissue  is  often  left  and  the  post-
reatment  PSA  concentration  may  not  be  zero,  even  if  a
adir  greater  than  0.2  ng/mL  represents  a  poor  prognosis
8].  Some  teams  use  the  Phoenix  criteria  [3,9]. Recently,
he  Stuttgart  criteria  deﬁned  recurrence  after  focused  ultra-
ound  as  a  rise  in  PSA  concentration  of  1.2  ng/mL  above  the
adir  [10]. However,  the  methodology  used  to  arrive  at  this
eﬁnition  is  debatable.
Table  1  Deﬁnition  of  biochemical  failure  after  prostate  canc
Treatment  Consensus  deﬁnition  
Radical  prostatectomy PSA  >  0.2  ng/mL
External  beam  radiotherapy  PSA  >  nadir  +  2  ng/mL  (Phoenix
Focused  ultrasound  
Cryotherapy  
Brachytherapy  
b
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fter cryotherapy
gain,  there  is  no  deﬁnition  of  biochemical  failure  after  this
ype  of  treatment.  Many  teams  use  the  ASTRO  guidelines  or
 PSA  threshold  of  0.5  ng/mL,  but  without  any  real  scientiﬁc
ustiﬁcation  [5].  As  cryotherapy  produces  the  same  histo-
ogical  lesion  as  focused  ultrasound,  it  would  be  logical  for
he  deﬁnition  of  biochemical  failure  to  be  the  same  for  both
echniques.
fter brachytherapy
hanges  in  the  PSA  level  in  this  case  are  complex.  It
ecreases  slowly  with  a  nadir  reached  after  2  to  4  years.
emporary  rebound  in  PSA  concentration  may  occur  12  to  24
onths  after  implantation  in  30  to  60%  of  patients.  It  rarely
xceeds  2  ng/mL  and  lasts,  on  average,  for  1  year  before  the
SA  concentration  falls  again.  The  cause  of  this  rebound  is
till  under  discussion,  but  it  does  not  seem  to  have  prognos-
ic  value  [11]. The  ASTRO  guidelines  have  been  abandoned
nd  replaced  by  the  Phoenix  criteria,  as  long  as  allowances
re  made  for  post-therapeutic  rebound  [12].
 prerequisite: detection of
icrometastases
 patient  with  biochemical  failure  may  have  local  or
etastatic  recurrence,  or  both.  Reasonably  eliminating
etastases  is  therefore  essential  before  submitting  the
atient  to  local  salvage  treatment,  because  morbidity  due
o  these  treatments  is  signiﬁcant.
urrent evaluation of the risk of
icrometastases
t  must  indeed  be  remembered  that  biochemical  failure  is  a
ery  early  indicator  that  precedes  the  appearance  of  clinical
etastasis  by  several  years  (on  average,  by  8  years  after
rostatectomy  and  7  years  after  radiotherapy)  [13,14].  Ifer  treatment.
Deﬁnitions  proposed  but  not  consensual
 criteria)
PSA  >  nadir  +  2  ng/mL  (Phoenix  criteria)
PSA  >  nadir  +  1.2  ng/mL  (Stuttgart  criteria)
Three  consecutive  PSA  increases  (ASTRO
guidelines)
PSA  >  0.5  ng/mL
PSA  >  nadir  +  2  ng/mL
(Phoenix  criteria)
y  the  usual  imaging  techniques  (bone  scan,  abdominopelvic
T).
Imaging  techniques  for  local  recurrence  of  prostate  cancer  
Table  2  Factors  pointing  towards  metastatic  develop-
ment  in  the  event  of  biochemical  failure.
Factors  favouring
metastatic  development
Factors  related  to  the
initial  tumour
(before  ﬁrst
treatment)
Gleason  score  ≥  8
T3-T4  stage
PSA  ≥  20  ng/mL
Time  interval  between
initial  treatment  and
biochemical  failure
Free  interval  between
treatment  and  biochemical
failure  less  than  2  to  3  years
Factors  related  to  the
PSA  concentration  at
the  time  of
biochemical  failure
Concentration  ≥  10  ng/mL
Velocity  ≥  2  ng/mL  per  year
Doubling  time  less  than  8  to
12  months
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and  89.3  to  100%  for  T2  combined  with  dynamic  imaging
[20,21].  Looking  for  high  choline  peaks  using  spectroscopyWe  therefore  make  do  at  the  present  time  with
probabilistic  reasoning  founded  on  clinical/laboratory  and
histopathological  criteria  based  on  the  characteristics  of
the  initial  tumour  and  on  the  PSA  kinetics  at  the  time
of  the  biochemical  failure  (Table  2).  The  more  metastatic
risk  factors  a  patient  accumulates,  the  less  relevant
it  becomes  to  offer  him  local  salvage  treatment  (and
therefore  to  look  for  local  recurrence  using  imaging)
[5].
New imaging techniques
Many  imaging  techniques  are  currently  being  used  to  try
to  move  forward  from  this  probabilistic  reasoning  and
detect  metastases  earlier:  NaF  scintigraphy,  PET-scans
with  choline  or  acetate,  whole-body  diffusion  magnetic
resonance  imaging  (MRI),  spinal  MRI,  lymph  node  MRI  with
iron  oxide  particles  etc.  It  is  not  our  intention  to  study  them
in  detail  in  this  article.  While  they  all  offer  the  prospect
of  selecting  candidates  for  local  salvage  treatment  better,
there  is  no  ofﬁcial  recommendation  at  the  present  time
concerning  their  use.
In  our  experience,  while  MRI  of  the  whole  spine  and
pelvis  in  conventional  sequences  (T1,  T2,  T1  with  gadolin-
ium  injection)  ignores  costal  metastases,  (rare)  long  bone
metastases  and  lymph  node  metastases,  it  does  have  the
advantages  of  being  feasible  within  a  reasonable  time,
of  being  more  sensitive  than  scintigraphy  and  of  allowing
abnormalities  detected  to  be  characterised.  We  use  it  more
and  more  in  patients  with  biochemical  failure  who  are  con-
sidered  at  risk  on  the  grounds  of  classic  clinical/laboratory
and  histopathological  criteria.
To  sum  up,  because  of  its  potential  morbidity,  salvage
treatment  of  a  local  recurrence  should  only  be  offered  to  a
patient  with  little  risk  of  already  having  micrometastases.
Patients  considered  to  be  at  risk  might  beneﬁt  from  new
imaging  techniques  which  seek  to  detect  metastases  as  early
as  possible,  even  though  there  is  currently  no  recommenda-
tion  on  the  subject.
(
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maging recurrence after radical
rostatectomy
he classic scheme
he  only  treatment  currently  approved  for  local  recur-
ence  after  prostatectomy  is  radiotherapy,  which  typically
elivers  66  Gy  to  the  prostatic  bed.  To  be  effective,  radio-
herapy  must  be  performed  early,  if  possible  while  the  PSA
oncentration  is  less  than  1  ng/mL  [5,15].
The  usefulness  of  histological  evidence  of  local  recur-
ence  is  still  being  debated.  Many  teams  do  not  take
ed  biopsies,  arguing  that  a  positive  biopsy  does  not  rule
ut  the  presence  of  metastases  and  a  negative  biopsy
oes  not  rule  out  local  recurrence.  The  classic  attitude
s  therefore  to  eliminate  those  patients  with  biochemical
ailure  with  a  high  risk  of  metastases  and  to  treat  the  rest
ith  radiotherapy, with  no  histological  evidence,  if  possible
efore  the  PSA  concentration  exceeds  1  ng/mL  [15].
In  this  classic  scheme  of  things,  there  is  no  place  for
maging.
he advantages of imaging
f  an  imaging  method  were  available  which  was  sensitive
nough  to  detect  local  recurrence  when  the  PSA  concentra-
ion  is  less  than  1  ng/mL,  and  reliable  enough  to  accurately
ocate  the  recurrence,  then  it  would  be  possible  to  apply  a
tereotactic  boost  to  the  recurrence,  focally  increasing  the
ose  above  66  Gy.
ransrectal ultrasound
his  technique  can  occasionally  show  local  recurrence  as
odular  deformation  of  the  tissue  coating  the  urethra,
hich  should  normally  be  regular.  It  can  also  show  remains
f  the  seminal  vesicles  (SVs)  left  in  place.  They  appear
ither  as  normal  vesicles,  with  a  liquid  content  and  a  typical
reolar  structure,  or  as  less  evocative,  oblong,  hypoechoic
odules  in  the  site  formerly  occupied  by  the  SVs  [16,17].
nfortunately,  ultrasound  is  not  very  sensitive.  This  results
n  low  sensitivity  for  ultrasound-guided  biopsies:  40  to  71%
hen  the  PSA  concentration  is  greater  than  1  ng/mL  and
nly  14  to  45%  when  it  is  below  this  threshold  [18,19].
agnetic resonance imaging (MRI)
RI,  on  the  other  hand,  has  recently  given  excellent  results
Figs.  1—3).  In  T2,  peri-urethral  ﬁbrosis  appears  as  a  coating
iving  a  homogeneous  hyposignal.  The  remains  of  the  SVs
ay  either  appear  liquid  giving  a  typical  hypersignal  or
brous  giving  a  hyposignal.  However,  it  is  dynamic  MRI  that
ifferentiates  well  between  local  recurrences  (which  are
nhanced  early  and  intensely)  and  postoperative  ﬁbrosis
which  is  not  or  very  little  enhanced).  Two  studies  involving
1  and  72  patients  with  a  mean  PSA  of  1.9  and  1.23  ng/mL
espectively,  reported  sensitivity  and  speciﬁcity  of  48  to
1.4%  and  52  to  82.1%  for  T2  imaging  and  84.1  to  88%there  is  no  longer  any  citrate  as,  in  theory,  no  healthy
rostate  tissue  remains)  can  also  be  useful.  In  a  study  on
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Figure 1. A 70-year-old patient who had had a radical prostatectomy 3 years previously for a Gleason 8 prostatic adenocarcinoma. After
surgery, the PSA nadir was 0.09 ng/mL. Gradual increase again to 0.2 ng/mL: a: T2-weighted coronal slice; b: T2-weighted sagittal slice.
The magnetic resonance imaging (MRI) shows an almost intact seminal vesicle (SV) on the left. It has a normal T2 ﬂuid signal (white arrow).
Dynamic MRI (not shown) did not show any suspect enhancement of this seminal vesicle.
Figure 2. A 57-year-old patient who had had a prostatectomy 3 years previously for a Gleason 7 prostatic adenocarcinoma. After surgery,
the PSA nadir was 0 ng/mL. Gradual increase again to 0.32 ng/mL: a: T2-weighted axial magnetic resonance imaging (MRI) shows no abnor-
mality; b: the dynamic axial slice subtracted after injection of contrast agent detected early enhancement of the right side of the neck of
the bladder (arrow); targeted biopsies showed a Gleason 7 adenocarcinoma.
Figure 3. A 70-year-old patient who had had a radical prostatectomy and radiotherapy 3 years previously for a Gleason 7 pT3a prostatic
adenocarcinoma. The PSA nadir was 0 ng/mL. Gradual increase to 1.48 ng/mL, with the appearance of a left nodule on DRE: a: T2-weighted
axial magnetic resonance imaging (MRI) showing a nodule with an intermediate signal in the left vesicorectal angle (arrow); b: diffusion-
weighted axial slice (b = 2000s/mm2): the nodule exhibits clear diffusion restriction (arrowhead); c: dynamic axial slice after contrast agent
injection: enhancement is early and intense (curved arrow). Biopsy of the nodule showed a Gleason 8 adenocarcinoma.
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rImaging  techniques  for  local  recurrence  of  prostate  cancer  
70  patients,  the  sensitivity  and  speciﬁcity  of  dynamic  MRI
combined  with  spectroscopy  was  87%  and  94%  respectively
(as  against  71%  and  94%  for  dynamic  imaging  only)  [22].
In theory,  PET-CT  using  choline  or  acetate  could  also
detect  local  recurrence  [23,24]  but  the  problem  is  its  low
spatial  resolution  which  does  not  provide  precise  localisa-
tion.  Moreover,  it  seems  less  sensitive  than  MRI  when  the
PSA  concentration  is  below  1  ng/mL  [25].
MRI-guided  stereotactic  radiotherapy  protocols  should
emerge  in  the  coming  years.  They  could  signiﬁcantly
improve  radiotherapy  results  by  delivering  high  doses  to  the
tumour  while  minimising  side  effects  [26].
Imaging recurrence after radiotherapy
The different salvage treatments
Treatment  of  local  recurrence  after  radiotherapy  is  difﬁcult.
Salvage  prostatectomy  is  possible  but  is  associated  with  con-
siderable  morbidity  and  in  practice  only  a  few  teams  in  the
world  practice  it  [27,28].  Cryotherapy,  focused  ultrasound
and  even  brachytherapy  have  been  used.  These  treatments
are  still  associated  with  a  much  higher  rate  of  morbidity
when  used  in  irradiated  patients  than  when  used  as  ﬁrst-line
treatment  [5].  However,  it  should  be  noted  that  for  focused
ultrasound,  it  has  been  possible  to  deﬁne  parameters  for
speciﬁc  shots  in  irradiated  patients,  which  has  substantially
reduced  morbidity.  The  rate  of  grade  3  urinary  incontinence
decreased  from  11%  to  9%,  the  need  to  ﬁt  an  artiﬁcial  sphinc-
ter  from  20%  to  6%  and  the  rate  of  urethrorectal  ﬁstula  from
9%  to  0%  [29].
Nevertheless,  there  remains  a  risk  with  salvage  treat-
ment  after  radiotherapy,  and  in  the  ﬁrst  place,  patients  with
a  low  risk  of  metastasis  should  be  selected  and  secondly,
the  recurrence  should  be  located  as  early  and  as  precisely
as  possible.  Because  of  the  morbidity  of  salvage  therapy,
it  is  also  important  to  treat  only  patients  for  whom  there
is  biopsy  evidence  of  recurrence,  since  it  is  now  clear  that
a  biopsy  after  radiotherapy  can  be  interpreted  as  long  as
this  is  done  at  least  18  months  after  the  radiation  treat-
ment.
The advantages of imaging
If  an  imaging  technique  can  detect  local  recurrence  early
with  accurate  localisation,  it  will  play  an  essential  role  in
managing  these  patients,  conﬁrming  the  recurrence  and
guiding  biopsies  and  possible  salvage  treatment.
Ultrasonography
Unfortunately,  ultrasonography  is  not  reliable  enough  to
hope  to  play  this  role.
Magnetic resonance imaging (MRI)
A  T2-weighted  MRI  shows  a  prostate  as  a  diffuse  hyposig-
nal,  with  loss  of  the  differentiation  between  the  peripheral
and  transition  zones,  and  detection  of  recurrences  (which
also  appear  as  a  hyposignal)  remains  difﬁcult.  On  the  other
hand,  dynamic  MRI,  in  which  there  is  excellent  contrast
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etween  the  recurrence  (which  is  often  hypervascular)  and
ost-radiation  ﬁbrosis  (hypovascular)  has  given  very  promis-
ng  results  (Figs.  4—6)  [30,31].  Indeed,  it  correlates  well
ith  biopsy  results  and  has  good  inter-reader  agreement
30].
Here  again,  spectroscopy  could  be  of  assistance.  After
ffective  radiotherapy,  there  is  metabolic  atrophy  with  dis-
ppearance  of  the  choline,  creatine,  citrate  and  polyamine
eaks.  The  reappearance  of  a  choline  peak  appears  to  be  a
ood  sign  of  recurrence  [32]. However,  for  reasons  that  are
till  unknown,  it  seems  that  some  irradiated  benign  glands
an  retain  high  levels  of  choline.  The  speciﬁcity  of  spec-
roscopy  may  not  therefore  be  perfect.  In  a  short  series
f  nine  patients  who  underwent  salvage  prostatectomy,
he  sensitivity  and  speciﬁcity  of  T2  MRI  was  68%  and  96%
espectively,  compared  with  77%  and  78%  for  spectroscopy
33].
Diffusion  imaging  also  appears  to  show  recurrence.  Its
ssociation  with  T2  MRI  increases  the  detection  sensi-
ivity  from  25%  to  62%  and  speciﬁcity  from  92%  to  97%
34].
Gradually,  therefore,  it  is  becoming  possible  to  offer
ultiparametric  MRI  combining  T2,  dynamic  and  dif-
usion  imaging.  By  combining  these  three  sequences,
rumainayagam  et  al.  obtained  excellent  correlation  with
aturation  biopsies  in  13  patients.  The  area  under  the  ROC
urve  was  0.77  to  0.89  depending  on  the  readers  for  all
ancers  and  0.86  to  0.93  for  recurrences  associated  with
iopsies  invaded  over  more  than  3  mm  [35].
These  good  results  should  make  multiparametric  MRI  an
ssential  examination  in  all  patients  with  suspected  recur-
ence  after  radiotherapy.
maging recurrence after focused
ltrasound treatment
he different salvage treatments
ne  of  the  advantages  of  focused  ultrasound  treatment  is
hat  it  can  be  repeated.  It  only  delivers  heat;  there  is
o  cumulative  dose  problem  as  with  radiotherapy  so  that
epeating  treatment  as  often  as  necessary  can  be  envisaged.
n  practice,  morbidity  increases  with  the  number  of  treat-
ents  [36]  so  that  two  treatment  sessions  are  the  limit.
nother  alternative  in  the  event  of  local  recurrence  after
ocused  ultrasound  is  to  use  radiotherapy,  which  gives  good
esults  with  acceptable  morbidity  [37].
One  of  the  limitations  of  focused  ultrasound  treat-
ent  is  that  with  current  equipment,  we  cannot  destroy
issue  beyond  the  ﬁxed  focal  point.  As  the  trans-
ucer  is  intra-rectal,  anterior  tumours  may  be  poorly
estroyed.  It  is  therefore  important  to  accurately  locate
he  recurrence,  particularly  whether  it  is  anterior,  to
ecide  between  retreatment  with  focused  ultrasound,  or
adiotherapy.he advantages of imaging
n  imaging  technique  detecting  and  locating  recurrences  is
hus  essential.
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Figure 4. A 79-year-old patient who had had external beam radiotherapy (76 Gy) and hormone treatment 6 years previously for a Gleason 7
prostate adenocarcinoma. The PSA nadir was 0.6 ng/mL, then the level gradually climbed again to 2.7 ng/mL: a: T2-weighted axial magnetic
resonance imaging (MRI) shows a suspect hyposignal area in the right mid part of the peripheral zone (arrow): b: diffusion-weighted axial
slice (b = 2000s/mm2); this area exhibits clear diffusion restriction (arrowhead); c: the dynamic axial slice after contrast agent injection
shows early enhancement (curved arrow). Targeted biopsies showed a right mid Gleason 7 adenocarcinoma.
Figure 5. A 73-year-old patient treated with external beam radiotherapy for prostate adenocarcinoma 8 years previously. The nadir PSA
was 0.85 ng/mL 2 years after radiotherapy, then the level gradually climbed again to 1.67 ng/mL. Biopsies of the prostate showed a Gleason
6 adenocarcinoma in the right apex, right and left mid parts of the prostate: a: T2-weighted axial magnetic resonance imaging (MRI) shows
a suspect hyposignal area in the right mid part of the peripheral zone (arrow); b: dynamic axial slice after contrast agent injection shows
early enhancement of the apex and the right mid part crossing the midline towards the left (arrowheads).
Figure 6. A 65-year-old patient treated with radio-hormonal therapy 4 years previously for a Gleason 6 prostatic adenocarcinoma with a
PSA of 20 ng/mL. The PSA nadir was 0.1 ng/mL and the level gradually climbed again to 3.5 ng/mL: a: T2-weighted axial magnetic resonance
imaging (MRI) shows a discrete hyposignal in the right mid part of the peripheral zone (arrow); b: the dynamic axial slice after contrast
agent injection shows early enhancement of the entire right mid part (arrowhead). Biopsies showed a Gleason 7 prostatic adenocarcinoma
of the right mid part.
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Figure 7. A 78-year-old patient treated with focused ultrasound 6 years previously for a Gleason 7 prostatic adenocarcinoma with a PSA
of 20 ng/mL. After a PSA nadir at 0 ng/mL, the level rose again progressively to 3 ng/mL: a: T2-weighted axial slice showing a right basal
nodule as a discrete hyposignal (arrow); b: axial section, ADC map: the nodule is much more visible (arrowhead); c: the dynamic axial slice
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mid part and the right base.
Ultrasonography
This  technique  is  not  reliable,  but  Doppler  colour  makes
detection  of  recurrent  cancers  a  little  more  sensitive,
although  the  sensitivity  of  the  ultrasound/Doppler  combi-
nation  is  still  low  (around  30%)  [38].
Magnetic resonance imaging (MRI)
T2-weighted  MRI  is  not  very  reliable.  Dynamic  MRI  greatly
increases  detection  sensitivity  by  showing  foci  of  recurrence
as  nodules  with  early  enhancement  (Figs.  7  and  8)  [39]. T2-
weighted  dynamic  MRI  is  thus  signiﬁcantly  more  sensitive
than  the  ultrasound/Doppler  combination  [40]. However,
dynamic  MRI  is  a  little  lacking  in  speciﬁcity.  It  is  difﬁcult
to  categorically  decide  between  a  recurrent  cancer  and
any  poorly  destroyed  anterior  adenomatous  tissue.  Diffusion
imaging  appears  to  be  more  speciﬁc  than  dynamic  imaging,
but  it  is  decidedly  less  sensitive  [41]. Spectroscopy  does  not
t
r
bw). Targeted biopsies showed a Gleason 7 adenocarcinoma of the
eem  to  be  useful,  but  there  are  only  few  data  on  the  subject
42].
In  practice,  dynamic  MRI  still  appears  to  be  the  most
seful  for  detecting  suspect  foci.  Given  its  lack  of  speci-
city,  guided  biopsies  should  always  be  used  to  conﬁrm
 recurrent  cancer  before  deciding  on  salvage  treat-
ent.
maging recurrence after cryotherapy
here  are  very  few  data  on  the  imaging  of  recurrence
fter  cryotherapy.  Ultrasound  and  T2-weighted  MRI  are  not
ery  reliable  [43,44].  As  the  histological  lesions  induced  by
ocused  ultrasound  and  cryotherapy  are  the  same,  it  is  likely
hat  dynamic  MRI  would  also  be  reliable  for  detecting  recur-
ence  after  cryotherapy.
Spectroscopy  might  be  useful  [43], but  that  remains  to
e  conﬁrmed.
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Figure 8. A 75-year-old patient treated with focused ultrasound 2 years previously for a Gleason 6 prostate adenocarcinoma with a
PSA of 8.3 ng/mL. The persistence of high PSA concentrations (5 ng/mL) led to discovery in the biopsy of residual cancer of the right mid
part treated by a second course of focused ultrasound. Despite this second treatment, the PSA concentration remained at 5 ng/mL: a:
T2-weighted axial slice showing no clear anomaly; b: the dynamic axial slice after contrast agent injection shows a left anterior-basal
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maging recurrence after brachytherapy
he different salvage treatments
nce  again,  the  literature  contains  very  few  data  on  the
ubject  of  post-brachytherapy  local  recurrence  because,  for
 long  time,  there  was  no  treatment  for  it  and  hence,  no
nterest  in  its  early  detection.
Things  change,  and  brachytherapy  failures  are  no  longer
herapeutic  dead  ends.  Prostatectomy  is  possible  but  difﬁ-
ult.  A  few  trials  of  high  dose  rate  brachytherapy  salvage
reatment  have  been  reported  [45]. Focused  ultrasound  can
lso  be  used,  with  very  good  results,  according  to  our  expe-
ience.
Because  there  are  beginning  to  be  salvage  solutions,  early
etection  of  local  recurrence  is  becoming  important.  Uncer-
ainty  about  the  best  criterion  of  biochemical  failure,  the
roblem  of  PSA  rebound  between  12  and  24  months,  means
hat  it  is  wise  to  obtain  biopsies  before  speaking  of  recur-
ence.  In  addition,  when  the  PSA  level  remains  high  or  rises
ore  than  30  months  after  treatment,  biopsies  should  be
erformed  to  search  for  recurrence  [46,47].
dvantages of magnetic resonance imaging
MRI)
n  a  T2-weighted  MRI,  the  prostate  is  dedifferentiated  with
 diffuse  hyposignal  [48]. This  sequence  is  thus  of  little
se.
Spectroscopy  can  show  metabolic  atrophy,  as  after  radio-
herapy.  The  persistence  of  metabolic  activity  beyond  2
ears  points  to  recurrence,  especially  if  it  is  focused
47,49].
Dynamic  MRI  can  also  show  that  cancers  have  disappeared
fter  treatment  and  detect  recurrence  as  persistent  areas  of
arly  enhancement  or  areas  reappearing  at  a  distance  from
he  implantation  [5].  In  our  experience,  this  is  a  simple  and
ensitive  method  for  detecting  recurrence  (Fig.  9).
d
r
f showed a Gleason 6 prostatic adenocarcinoma.
ocal treatments: the radiologist in the
ront line?
ynamic magnetic resonance imaging (MRI):
he most reliable sequence
n  short,  dynamic  MRI  seems  currently  to  be  the  most  use-
ul  technique  for  detecting  local  recurrence  of  prostate
ancer  early,  regardless  of  the  initial  treatment.  Diffu-
ion  MRI  and  spectroscopy  may  be  able  to  improve  the
iagnosis,  but  that  remains  to  be  conﬁrmed.  In  general,
t  appears  that  detecting  local  recurrence  by  imaging  is
asier,  paradoxically,  than  initial  detection  of  a  cancer.
his  is  above  all  due  to  the  very  different  enhancement
atterns  of  recurrent  cancer  and  ﬁbrosis  (post-surgical,
ost-radiation  or  post-coagulation  necrosis).  The  indications
or  imaging  after  treatment  could  therefore  have  to  change
apidly.
ndications for imaging in the future
 new  development  may  in  fact  somewhat  complicate  the
ituation.  It  is  becoming  clear  that  a  number  of  patients
ith  limited  prostate  cancer  could  be  offered  focal  treat-
ent  in  which  only  the  focus  of  the  tumour  is  targeted  [50]:
etween  the  two  extremes  of  active  surveillance  and  radical
reatment,  there  must  be  a  middle  way.
However,  if,  instead  of  removing  or  destroying  the  entire
land,  only  a  sector  containing  the  tumour  is  destroyed  (e.g.
sing  focused  ultrasound  or  brachytherapy),  it  is  probable
hat  the  PSA  concentration  will  vary  little  after  treatment.
he  very  notion  of  biochemical  failure  could  henceforth
ose  its  meaning  and  imaging  will  ﬁnd  itself  in  the  front
ine  for  monitoring  changes  in  the  area  treated,  verifying
estruction  of  the  tumour  and  ensuring  there  are  no  recur-
ences.
What  will  be  the  best  imaging  techniques  for  this
ollow-up?  How  often  should  we  monitor  patients?  It  is
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Figure 9. A 71-year-old patient treated with brachytherapy 8 years previously for a Gleason 6 prostatic adenocarcinoma with a PSA
concentration of 8 ng/mL. Slow increase again in PSA to 5 ng/mL; a and b: T2-weighted axial magnetic resonance imaging (MRI) revealing
 axial slices after injection of contrast agent showing a peripheral area
here is bilateral early enhancement (Fig. 9d,  curved arrows). Note that
rrowheads).
• T2-weighted  MRI  is  generally  not  very  accurate.
• Dynamic  MRI  has  shown  very  promising  results
after  prostatectomy,  after  radiotherapy  and  after
focused  ultrasound,  given  the  good  contrast  between
the  hypervascular  recurrent  cancer  and  typically
hypovascular  post-treatment  ﬁbrosis.
C
T
f
r
m
o
3
Qa dedifferentiated prostate with no suspect area; c and d: dynamic
which is not enhanced (Fig. 9c,  arrow), except at the apex where t
the brachytherapy grains appear as small signal voids (Fig. 9a—d, a
too  early  to  answer  these  questions,  but  the  issue  of
evaluation  of  focal  treatment  of  prostate  cancer  is  cer-
tain  to  be  one  of  the  burning  questions  of  the  next  few
years.
TAKE-HOME  MESSAGES
General  concepts
• Whatever  the  initial  treatment,  there  are  now
salvage  solutions  for  cases  of  local  recurrence  of
prostate  cancer.
• The  deﬁnition  of  biochemical  failure  after  radical
prostatectomy  is:  PSA  greater  than  0.2  ng/mL.
• The  deﬁnition  of  biochemical  failure  after
radiotherapy  is:  PSA  greater  than  nadir  +  2  ng/mL.
• There  is  no  consensus  deﬁnition  of  biochemical
failure  after  treatment  with  focused  ultrasound,
cryotherapy  or  brachytherapy.
Detection  of  local  recurrence  by  imaging
• Ultrasound  and  techniques  derived  from  it  are  not  atpresent  reliable. 1
2• The  role  of  diffusion  MRI  and  spectroscopy  remains
to  be  deﬁned.
linical case
his  63-year-old  patient  was  treated  11  years  previously
or  a  Gleason  6  T3N0M0  prostatic  adenocarcinoma  by
adiotherapy  (65  Gy).  The  PSA  concentration  before  treat-
ent  was  23.5  ng/mL.  The  PSA  nadir  (1.81  ng/mL)  was
btained  after  3  years.  PSA  concentration  is  currently
.91  ng/mL.
uestions.  Does  the  patient  categorically  have  a biochemical
failure?
.  A  multiparametric  MRI  was  performed  (Fig.  10).  How  do
you  interpret  it?
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Figure 10. Axial multiparametric magnetic resonance imaging (MRI) of the prostate passing through the middle part the gland (a—c) and
through the root of the seminal vesicles (SV) (d—f), T2-weighted (a and d), in diffusion (b = 2000s/mm2, b and e) and in T1 after contrast
a
3
A
1
2
3
D
T
c
Rgent injection (dynamic imaging, c and f).
.  What  do  you  recommend  before  being  able  to  decide  on
the  best  management?
nswers
.  After  radiotherapy,  the  current  deﬁnition  of  biochemical
failure  is  nadir  +  2  ng/mL  (Phoenix  criteria).  The  patient
therefore  has  a  biochemical  failure;
.  Two  abnormalities  can  be  seen:
•  a  nodule  in  the  right  mid  part  of  the  peripheral  area
with  all  the  characteristics  of  a  tumour  lesion:  T2
hyposignal  (Fig.  10a), diffusion  restriction  (Fig.  10b)
and  early  contrast  uptake  (Fig.  10c),
• the  appearance  of  the  right  SV  is  suspect:  it  like-
wise  has  the  features  of  a  tumour  lesion  in  the  three
sequences  (Fig.  10d—f);
.  Prostate  biopsies  are  needed  for  evidence  of  the  local
recurrence.  They  will  be  randomised  samples  scattered
over  the  prostate  and  biopsies  guided  by  the  MRI  data
(mid  right  part  and  right  SV).isclosure of interest
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oncerning  this  article.eferences
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